Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR6390 + letrozole + anastrozole
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SHR6390 + letrozole + anastrozole is an experimental combination regimen investigated for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. SHR6390, also known as dalpiciclib, is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor. Letrozole and anastrozole are nonsteroidal aromatase inhibitors that decrease estrogen synthesis, which is essential for hormone-sensitive breast cancer growth. This combination leverages both targeted cell cycle inhibition (via CDK4/6 blockade) and suppression of estrogen production, offering a comprehensive approach to hormonal breast cancer therapy. The combination has been evaluated in early-phase (IB/II) and phase III clinical trials, showing promising antitumor activity and acceptable safety profiles in this patient population[1][3][5][7][9].
- Other names
- DALPICICLIB + letrozole + anastrozole
02
Targets
CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on SHR6390 + letrozole + anastrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR6390 + letrozole + anastrozole.